{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-055322","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.608417+00:00","generated_at":"2026-05-20T02:43:51.998158+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Verastem reports 83% ORR in RAMP 205 PDAC trial; details VS-7375 KRAS G12D inhibitor","bullets":["FDA approved avutometinib + defactinib (AVMAPKI/FAKZYNJA) on May 8, 2025 for KRAS-mutated recurrent LGSOC.","RAMP 205 Phase 1/2 in first-line mPDAC: 83% unconfirmed ORR (10/12) at dose level 1; all patients had tumor shrinkage.","RP2D set: avutometinib 2.4mg, defactinib 200mg, gemcitabine 800mg/m2, nab-paclitaxel 125mg/m2.","VS-7375: oral KRAS G12D ON/OFF inhibitor with potent preclinical selectivity and activity; Phase 1/2a trial planned.","Preliminary data suggest patients may exceed historical median PFS for gemcitabine/nab-paclitaxel."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-055322","json":"https://secwatch.observer/filing/0001104659-25-055322.json","markdown":"https://secwatch.observer/filing/0001104659-25-055322.md","text":"https://secwatch.observer/filing/0001104659-25-055322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925055322/0001104659-25-055322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925055322/tm2516844d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:43:51.998158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}